Rewired proteostasis in KRAS inhibitor resistance

被引：0
|
作者：
Eccleston, Alex
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2023年 / 22卷 / 11期
关键词：
D O I：
10.1038/d41573-023-00155-0
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：871 / 871
页数：1
相关论文
共 50 条
  • [21] Chromatin condensation in KRAS-mutant lung cancer as a therapeutic target: challenging the paradigm of associating KRAS mutation with EGFR inhibitor resistance
    Wang, Meng
    Kern, Ashley M.
    Huelskoetter, Marieke
    Greninger, Patricia
    Singh, Anurag
    Pan, Yunfeng
    Chowdhury, Dipanjan
    Krause, Mechthild
    Baumann, Michael
    Benes, Cyril H.
    Efstathiou, Jason A.
    Settleman, Jeff
    Willers, Henning
    CANCER RESEARCH, 2014, 74 (19)
  • [22] Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma
    Ferguson, Ian D.
    Lin, Yu-Hsiu T.
    Lam, Christine
    Shao, Hao
    Tharp, Kevin M.
    Hale, Martina
    Kasap, Corynn
    Mariano, Margarette C.
    Kishishita, Audrey
    Escobar, Bonell Patino
    Mandal, Kamal
    Steri, Veronica
    Wang, Donghui
    Phojanakong, Paul
    Tuomivaara, Sami T.
    Hann, Byron
    Driessen, Christoph
    Van Ness, Brian
    Gestwicki, Jason E.
    Wiita, Arun P.
    CELL CHEMICAL BIOLOGY, 2022, 29 (08) : 1288 - +
  • [23] Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma
    Ferguson, Ian
    Lin, Tony
    Lam, Christine
    Shao, Hao
    Tharp, Kevin
    Van Ness, Brian
    Gestwicki, Jason
    Wiita, Arun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S90 - S90
  • [24] Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
    Adachi, Yuta
    Kimura, Ryo
    Hirade, Kentaro
    Ebi, Hiromichi
    CANCERS, 2021, 13 (20)
  • [25] Mechanisms of Resistance to MEK Inhibitor AZ6244 in KRAS Mutant Metastatic Colorectal Cancer
    Gambino, V.
    Sun, C.
    Prahallad, A.
    Tzani, A.
    Grernrum, W.
    Mittempergher, L.
    Bernards, R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 174 - 174
  • [26] Strategies to overcome resistance to BET bromodomain inhibitor in KRAS/LKB1 mutant NSCLC
    Soucheray, M.
    Kikuchi, E.
    Pulido, I.
    Akbay, E.
    Becker, J. H.
    Christensen, C. L.
    Johnson, N.
    Patel, T. B.
    Carretero, J.
    Wong, K. K.
    Shimamura, T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 191 - 191
  • [27] Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity
    Freed-Pastor, William A.
    Aguirre, Andrew J.
    CANCER CELL, 2022, 40 (09) : 908 - 910
  • [28] Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor
    Hofmann, Marco H.
    Jurado, Sabine
    Gerlach, Daniel
    Koga, Takamasa
    Trapani, Francesca
    Gmachl, Michael
    Alpar, Donat
    Lieb, Simone
    Jeschko, Astrid
    Mitsudomi, Tetsuya
    Kraut, Norbert
    Petronczki, Mark P.
    CANCER RESEARCH, 2022, 82 (12)
  • [29] Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance
    Jiang, Zhiyan
    Li, Yan
    Zhou, Xin
    Wen, Jie
    Zheng, Pengwu
    Zhu, Wufu
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 100
  • [30] A single inhibitor for all KRAS mutations
    Ryan B. Corcoran
    Nature Cancer, 2023, 4 : 1060 - 1062
12345